Status:
COMPLETED
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Lead Sponsor:
Human Genome Sciences Inc., a GSK Company
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Mapatumumab is a fully human, agonist monoclonal antibody that activates the cell death pathway in tumor cells by specifically binding to TRAIL-R1 with high affinity. Sorafenib, a multikinase inhibito...
Eligibility Criteria
Inclusion
- Child-Pugh Class A.
- Barcelona Clinic Liver Cancer (BCLC) advanced stage (C) hepatocellular carcinoma, or BCLC intermediate stage (B) hepatocellular carcinoma if treatment with transarterial chemoembolization is not considered appropriate
- Measurable disease demonstrating intratumoral arterial enhancement by contrast enhanced computerized tomography (CT), with use of multislice scanners, or contrast enhanced dynamic magnetic resonance imaging (MRI), with at least 1 tumor lesion that meets the following criteria: located in the liver; can be accurately measured in at least 1 dimension; well delineated area of viable, hypervascular (contrast enhancement in the arterial phase) tumor that is \>2 centimeter (cm) in the axial plane; suitable for repeat measurement; OR not previously treated with locoregional or systemic treatment unless the lesion shows a well-delineated area of viable (contrast enhancement in the arterial phase) tumor that is \>2 cm in the axial plane. (If the lesion is poorly demarcated or exhibits atypical enhancement as a result of the previous intervention, then it cannot be selected as a target lesion)
- Radiologic eligibility (measurable disease) must be must be confirmed by the BICR prior to randomization.
- Adequate bone marrow, renal and liver function as defined in the protocol.
- Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale
- Age 18 years or older
- Have the ability to understand the requirements of the study, provide written informed consent (including consent for the use and disclosure of research-related health information), and comply with the study and follow-up procedures.
Exclusion
- Any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complications or reduces the possibility of assessing clinical effect.
- Received prior investigational or non-investigational cytotoxic chemotherapy, hormonal therapy, biological therapy (including but not limited to monoclonal antibodies, small molecules or other immunotherapy) to treat hepatocellular carcinoma.
- History of organ allograft.
- Previously received mapatumumab or sorafenib.
- Underwent resection, radiofrequency ablation, radiation or chemoembolization within 4 weeks before enrollment or not recovered from such treatments.
- Need for concomitant anticancer therapy (surgery, radiation therapy, chemotherapy, immunotherapy, radiofrequency ablation) or other investigational agents during the study treatment period.
- Major surgery (i.e., the opening of a major body cavity, requiring the use of general anesthesia) within 4 weeks before enrollment; minor surgery (except for insertion of vascular access device) within 2 weeks before enrollment; or not yet recovered from the effects of the surgery.
- Systemic steroids within 1 week before enrollment except steroids used as part of an antiemetic regimen or maintenance-dose steroids for non-cancerous disease.
- Hepatic encephalopathy, per the investigator's evaluation.
- History of clinically significant gastrointestinal bleeding requiring procedural intervention (e.g., variceal banding, transjugular intrahepatic portosystemic shunt procedure, arterial embolization, topical coagulation therapy) within 4 weeks before enrollment.
- Gastrointestinal disease resulting in an inability to take oral medication or a requirement for intravenous hyperalimentation.
- History of any infection requiring hospitalization or intravenous antibiotics within 2 weeks before enrollment.
- Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids.
- Known human immunodeficiency virus infection.
- Unstable angina, myocardial infarction, cerebrovascular accident, \>= Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure within 6 months before enrollment.
- Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.
- Uncontrolled hypertension (systolic blood pressure \>150 millimeters of mercury \[mmHg\] or diastolic pressure \>90 mmHg despite optimal medical management).
- Using and unable to discontinue use of concomitant strong CYP3A4 inducers (e.g., including but not limited to St. John's Wort, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital)
- Pregnant female or nursing mother. All females with an intact uterus (unless amenorrheic for the 24 months before enrollment) must have a negative serum pregnancy test at screening. All non-sterile or non-postmenopausal females must practice a medically accepted method of contraception over the course of the study and for 60 days after the last dose of study agent.
- Males who do not agree to use effective contraception during the study and for a period of 60 days following the final dose of study agent.
- Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s) or subject is receiving other investigational agents.
- Acute or chronic severe renal insufficiency (glomoerular filtration rate \<30 milliliters \[mL\]/minute/1.73 square meters) or acute renal insufficiency of any severity due to the hepato-renal syndrome.
- Hepatitis B virus deoxyribonucleic acid (DNA) levels \>2,000 international units/mL.
Key Trial Info
Start Date :
February 8 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2017
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT01258608
Start Date
February 8 2011
End Date
November 29 2017
Last Update
December 19 2018
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Aurora, Colorado, United States, 80045
2
GSK Investigational Site
Shreveport, Louisiana, United States, 71103
3
GSK Investigational Site
Rochester, Minnesota, United States, 55905
4
GSK Investigational Site
Tupelo, Mississippi, United States, 38801